Biogen, Denali Start Phase 3 Study in Parkinson’s

 

• Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2
• LRRK2 mutations are one of the most common genetic drivers of Parkinson’s disease
• Targeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s disease

https://www.biospace.com/article/releases/biogen-and-denali-therapeutics-announce-initiation-of-the-phase-3-lighthouse-study-in-parkinson-s-disease-associated-with-lrrk2-pathogenic-mutations/